Ardelyx News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.02.25	Ardelyx Secures $5M Milestone After China Approves Tenapanor For CKD (RTTNews)
25.09.23	Ardelyx Says Japan Approves Tenapanor For Hyperphosphatemia (RTTNews)
02.08.23	Ardelyx Q2 Loss Narrows (RTTNews)
18.04.23	Ardelyx Resubmits NDA To FDA For Xphozah (RTTNews)
28.03.23	These Stocks Hit New 52-Week Highs Yesterday - Were You Ahead Of The Game? (RTTNews)
03.03.23	Pre-market Movers: BFRG, VERU, ARDX, GMVD, RKDA… (RTTNews)
02.02.23	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
29.12.22	Ardelyx: FDA Grants Appeal For XPHOZA (RTTNews)
29.12.22	FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) (PR Newswire)
28.12.22	Biotech Penny Stocks That Delivered Impressive Gains In 2022 (RTTNews)
23.12.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
17.12.22	Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis (PR Newswire)
22.11.22	Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference (PR Newswire)
17.11.22	Pre-market Movers: ARDX, GRTX, BBWI, PXMD, TNYA … (RTTNews)
17.11.22	Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dia... (PR Newswire)
16.11.22	Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis (PR Newswire)
04.11.22	National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels (PR Newswire)
03.11.22	Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
03.11.22	Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosp... (PR Newswire)
02.11.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
31.10.22	Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan (PR Newswire)
27.10.22	Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022 (PR Newswire)
26.10.22	Biotech Stocks Facing FDA Decision In November 2022 (RTTNews)
24.10.22	Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting (PR Newswire)
20.10.22	Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022 (PR Newswire)
30.09.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
06.09.22	Ardelyx to Participate in Upcoming Investor Conferences (PR Newswire)
04.08.22	Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
02.08.22	Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference (PR Newswire)
28.07.22	Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022 (PR Newswire)
01.07.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
30.06.22	Ardelyx To Receive Up To $20 Mln Financing Deal With HealthCare Royalty Partners (RTTNews)
30.06.22	Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners (PR Newswire)
21.06.22	Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 (PR Newswire)
03.06.22	Ardelyx to Present at the Jefferies 2022 Healthcare Conference (PR Newswire)
24.05.22	Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults (PR Newswire)
17.05.22	Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022 (PR Newswire)
16.05.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
05.05.22	Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights (PR Newswire)
28.04.22	Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022 (PR Newswire)
25.04.22	Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor) (PR Newswire)
12.04.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
11.04.22	Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor (PR Newswire)
07.04.22	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings (PR Newswire)
04.04.22	Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults (PR Newswire)
09.03.22	Ardelyx, Inc. Reports Employment Inducement Grants (PR Newswire)
03.03.22	Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference (PR Newswire)
28.02.22	Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights (PR Newswire)
24.02.22	Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners (PR Newswire)
22.02.22	Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	218.50	4.70 %	K V
Swisscom	530.00	2.02 %	K V
Givaudan	4’061.00	1.50 %	K V
Zurich Insur Gr	602.00	1.21 %	K V
Geberit	586.00	1.03 %	K V
Part Grp Hldg	1’292.00	-2.45 %	K V
Logitech Intl	83.14	-2.60 %	K V
UBS Group	28.41	-3.60 %	K V
Lonza Grp	544.20	-3.75 %	K V
CieFinRichemont	158.45	-3.88 %	K V

Nachrichten zu Ardelyx Inc

Aktien Top/Flop

Meistgelesene Nachrichten